68Ga-labelled peptides for diagnosis of neuroendocrine tumours;Les peptides marqués au 68Ga dans le diagnostic des tumeurs neuro-endocrines

Medecine Nucleaire

Volumn 37, Issue 3, 2013, Pages 66-70

  Cambioli, S ^a   Ambrosini, V ^a   Morigi, J J ^a   Tabacchi, E ^a   Fanti, S ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

68Ga DOTA peptides; Neuroendocrine tumours

Indexed keywords

6 FLUORODOPA F 18; FLUORODEOXYGLUCOSE F 18; GALLIUM 68; INDIUM 111; SOMATOSTATIN; SOMATOSTATIN RECEPTOR; TETRAXETAN; TETRAXETAN NOC GALLIUM GA 68; TETRAXETAN TATE GALLIUM GA 68; TETRAXETAN TOC GALLIUM GA 68; UNCLASSIFIED DRUG;

CLINICAL PRACTICE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; HUMAN; NEUROENDOCRINE TUMOR; SHORT SURVEY;

EID: 84875618990     PISSN: 09281258     EISSN: 18786820     Source Type: Journal    
DOI: 10.1016/j.mednuc.2013.01.007     Document Type: Short Survey

References (24)

1. Modlin I.M., Kidd M., Latich I., Zikusoka M.N., Shapiro M.D. Current status of gastrointestinal carcinoids. Gastroenterology 2005, 128:1717-1751.
2. Taal B.G., Visser O. Epidemiology of neuroendocrine tumours. Neuroendocrinology 2004, 80(Suppl 1):3-7.
3. Yao J.C., Hassan M., Phan A., Dagohoy C., Leary C., Mares J.E., et al. One hundred years after " carcinoid" : epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008, 26:3063-3072.
4. Reubi J.C. Neuropeptide receptors in health and disease: the molecular basis for in vivo imaging. J Nucl Med 1995, 36:25-35.
5. Jensen R.T. Endocrine tumors of the gastrointestinal tract and pancreas. Harrison's principles of internal medicine 2005, 2220-2231. McGraw-Hill, New York. 16th ed. D.L. Kasper, E. Braunwald, A.S. Fauci, S.L. Hauser, D.L. Longo, J.L. Jameson (Eds.).
6. Rindi G., Klöppel G., Alhman H., Caplin M., Couvelard A., de Herder W.W., et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006, 449:395-401.
7. Rindi G., Klöppel G., Couvelard A., Komminoth P., Körner M., Lopes J.M., et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2007, 451:757-762.
8. Travis W.D. Reporting lung cancer pathology specimens. Impact of the anticipated 7th edition TNM classification based on recommendations of the IASLC Staging Committee. Histopathology 2009, 54:3-11. IASLC Staging Committee.
9. Sundin A., Garske U., Orlefors H. Nuclear imaging of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 2007, 21:69-85.
10. Ramage J.K., Davies A.H., Ardill J., Bax N., Caplin M., Grossman A., et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut 2005, 54(Suppl. 4):iv1-iv16.
11. Krenning E.P., Kwekkeboom D.J., Bakker W.H., Breeman W.A., Kooij P.P., Oei H.Y., et al. Somatostatin receptor scintigraphy with [111InDTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993, 20:716-731.
12. Campana D., Ambrosini V., Pezzilli R., Fanti S., Labate A.M., Santini D., et al. Standardized uptake values of (68)Ga-DOTA-NOC PET: a promising prognostic tool in neuroendocrine tumors. J Nucl Med 2010, 51:353-359.
13. 18Fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumors. Eur J Nucl Med 1998, 25:79-83.
14. Cescato R., Schulz S., Waser B., Eltschinger V., Rivier J.E., Wester H.J., et al. Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists. J Nucl Med 2006, 47:502-511.
15. Antunes P., Ginj M., Zhang H., Waser B., Baum R.P., Reubi J.C., et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?. Eur J Nucl Med Mol Imaging 2007, 34:982-993.
16. 68Ga for medical application. J Nucl Med 2007, 48:1741-1748.
17. 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging 2010, 37:2004-2010.
18. 68Ga]DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007, 48:508.
19. 68Ga-DOTA-NOC uptake in the pancreatic head in a large series of extrapancreatic NET patients studied with sequential PET/CT. J Nucl Med 2011, 52:886-890.
20. 18F]DOPA PET for the detection of gastroenteropancreatic and lung neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2008, 35:1431-1438.
21. 18F]DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2009, 36:765-770.
22. 68Ga-DOTA-TOC PET/CT datasets demonstrates different degrees of differentiation. Eur J Nucl Med Mol Imaging 2007, 34:812.
23. 18F]FDG. Cancer 2008, 112:2447-2455.
24. 18F]FDG in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTA-TOC therapy. Eur J Nucl Med Mol Imaging 2006, 33:1115-1122.